Evidence map›Paper›PMID 40519747›Full record

ArticleGenetics in medicine open2025

Estimation of

Karen E Malone, Catherine Argyriou, Evelyn Zavacky, Nancy Braverman

Abstract read
In one paragraph

Article in Genetics in medicine open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karen E MaloneGeneScape, Leiden, The Netherlands.
Catherine ArgyriouDepartment of Human Genetics, McGill University, Montreal, QC, Canada.
Evelyn ZavackyResearch Institute of the McGill University Health Center, McGill University, Montreal, QC, Canada.
Nancy BravermanResearch Institute of the McGill University Health Center, McGill University, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Zellweger Spectrum Disorder (ZSD) is a rare syndromic disorder characterized by impaired peroxisome assembly and function. Many cases are due to pathogenic variants in the Methods: We utilized large-scale genetic diversity data sets to estimate the mutational burden per region and integrated genotype-phenotype relationships with real-world survival data to provide patient number estimates for severe, intermediate, and mild segments per age and country. Results: We observed regional differences in the variant landscapes expected to contribute to Conclusion: Notably, our model indicates that a significant proportion of patients with intermediate/mild phenotype may go unrecognized by current diagnostic practices. This diagnosis independent model of patient number estimates provides additional insights into the broad spectrum of

Indexed as

Heimler syndromePeroxisome biogenesis factor 1PEX1Zellweger spectrum disorder

Identifiers

PMID40519747
PMCPMC12166394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.